AU2019257651B2 - Pteridinone compounds and uses thereof - Google Patents

Pteridinone compounds and uses thereof Download PDF

Info

Publication number
AU2019257651B2
AU2019257651B2 AU2019257651A AU2019257651A AU2019257651B2 AU 2019257651 B2 AU2019257651 B2 AU 2019257651B2 AU 2019257651 A AU2019257651 A AU 2019257651A AU 2019257651 A AU2019257651 A AU 2019257651A AU 2019257651 B2 AU2019257651 B2 AU 2019257651B2
Authority
AU
Australia
Prior art keywords
abs
cancer
compound
ring
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019257651A
Other languages
English (en)
Other versions
AU2019257651A1 (en
Inventor
Guy Bemis
Michael Boyd
David Deininger
Hongbo Deng
Warren Dorsch
Wenxin Gu
Russell R. Hoover
Mac Arthur Johnson Jr.
David J. Lauffer
Mark Willem Ledeboer
Brian Ledford
Pan Li
Francois Maltais
Marina PENNEY
Darin TAKEMOTO
Nathan D. Waal
Tiansheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2019257651A1 publication Critical patent/AU2019257651A1/en
Application granted granted Critical
Publication of AU2019257651B2 publication Critical patent/AU2019257651B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019257651A 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof Active AU2019257651B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862661744P 2018-04-24 2018-04-24
US62/661,744 2018-04-24
PCT/US2019/028604 WO2019209757A1 (en) 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof

Publications (2)

Publication Number Publication Date
AU2019257651A1 AU2019257651A1 (en) 2020-10-15
AU2019257651B2 true AU2019257651B2 (en) 2023-05-25

Family

ID=66655428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019257651A Active AU2019257651B2 (en) 2018-04-24 2019-04-23 Pteridinone compounds and uses thereof

Country Status (11)

Country Link
US (3) US11059826B2 (https=)
EP (1) EP3784669B1 (https=)
JP (2) JP7479293B2 (https=)
CN (1) CN112218865B (https=)
AR (1) AR114828A1 (https=)
AU (1) AU2019257651B2 (https=)
CA (1) CA3097774A1 (https=)
ES (1) ES2969982T3 (https=)
IL (1) IL278122B2 (https=)
TW (1) TWI884914B (https=)
WO (1) WO2019209757A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
PL3919491T3 (pl) * 2019-01-29 2025-10-20 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor akt
EP4045498B1 (en) * 2019-10-14 2025-12-03 The Regents of the University of California Broad spectrum anti-cancer compounds
US20230322767A1 (en) 2020-07-29 2023-10-12 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
CN117088877A (zh) * 2020-10-28 2023-11-21 杭州阿诺生物医药科技有限公司 一种高活性Wnt通路抑制剂化合物
TW202334157A (zh) * 2022-01-29 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 一種Ｗｎｔ通路抑制劑化合物
TW202333697A (zh) * 2022-01-30 2023-09-01 大陸商杭州阿諾生物醫藥科技有限公司 Ｗｎｔ通路抑制劑化合物
CN114436918B (zh) * 2022-02-23 2023-05-23 郑州大学 环丁-1-烯胺类化合物及其制备方法和在药物中的应用
CN117396482B (zh) * 2022-07-28 2026-02-27 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
WO2024022365A1 (zh) * 2022-07-28 2024-02-01 杭州阿诺生物医药科技有限公司 一种Wnt通路抑制剂化合物
US20240217951A1 (en) * 2022-09-23 2024-07-04 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020722A1 (de) * 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2005123736A1 (de) * 2004-06-21 2005-12-29 Boehringer Ingelheim International Gmbh Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2015117055A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
AU2011226830A1 (en) * 2004-08-14 2011-10-13 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
JP6052527B2 (ja) 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉ
EP2958918B1 (en) 2013-02-21 2016-12-07 Boehringer Ingelheim International GmbH Dihydropteridinones ii
WO2015193229A1 (de) 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
CN105801582A (zh) * 2016-04-12 2016-07-27 合肥工业大学 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途
ES2969982T3 (es) * 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020722A1 (de) * 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2005123736A1 (de) * 2004-06-21 2005-12-29 Boehringer Ingelheim International Gmbh Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2015117055A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARG et al., "Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress", Molecular & Cellular Oncology. 2015, vol. 2, e975089-1 to e975089-20 *

Also Published As

Publication number Publication date
CN112218865B (zh) 2024-03-12
US12384790B2 (en) 2025-08-12
IL278122A (en) 2020-11-30
US20190322673A1 (en) 2019-10-24
ES2969982T3 (es) 2024-05-23
US11059826B2 (en) 2021-07-13
US20230312587A1 (en) 2023-10-05
WO2019209757A1 (en) 2019-10-31
US20220363685A1 (en) 2022-11-17
IL278122B1 (en) 2023-09-01
JP2023116712A (ja) 2023-08-22
JP7479293B2 (ja) 2024-05-08
TW202010744A (zh) 2020-03-16
US11572364B2 (en) 2023-02-07
EP3784669A1 (en) 2021-03-03
CA3097774A1 (en) 2019-10-31
TWI884914B (zh) 2025-06-01
EP3784669B1 (en) 2023-10-25
JP2021522237A (ja) 2021-08-30
IL278122B2 (en) 2024-01-01
AR114828A1 (es) 2020-10-21
CN112218865A (zh) 2021-01-12
AU2019257651A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
AU2019257651B2 (en) Pteridinone compounds and uses thereof
US12521438B2 (en) SMARCA degraders and uses thereof
US11779578B2 (en) IRAK degraders and uses thereof
JP7508584B2 (ja) ＰＩ３Ｋα阻害剤およびそれらの使用
CA3150108A1 (en) Hpk1 antagonists and uses thereof
AU2019360941B2 (en) TYK2 inhibitors and uses thereof
US20230089916A1 (en) Irak degraders and uses thereof
AU2024204726A1 (en) TYK2 inhibitors and uses thereof
US12606568B2 (en) SMARCA degraders and uses thereof
SG11202113154YA (en) Tead inhibitors and uses thereof
US20230087825A1 (en) Smarca degraders and uses thereof
US20240024318A1 (en) Smarca degraders and uses thereof
BR112020015328A2 (pt) Inibidores de gcn2 e usos dos mesmos
US20250375526A1 (en) Irak degraders and uses thereof
JP2021508703A (ja) Ｉｒａｋ分解剤およびそれらの使用
TW201238950A (en) NAMPT and rock inhibitors
US20240383868A1 (en) Smarca degraders and uses thereof
JP2025519029A (ja) ＰＩ３Ｋα阻害剤及びその使用方法
CA3206501A1 (en) Gpr84 antagonists and uses thereof
US20240293423A1 (en) Stat degraders and uses thereof
CA3266321A1 (en) HETEROBORCTIONAL COMPOUNDS AND METHODS OF DISEASE TREATMENT
US20250375460A1 (en) Stat degraders and uses thereof
CN108191857B (zh) 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂
EA049284B1 (ru) ИНГИБИТОРЫ PI3Kα И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN117915912A (zh) Hpk1拮抗剂和其用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LAUFFER, DAVID J.; BEMIS, GUY; BOYD, MICHAEL; DEININGER, DAVID; DENG, HONGBO; DORSCH, WARREN; GU, WENXIN; HOOVER, RUSSELL R.; JOHNSON JR., MAC ARTHUR; LEDEBOER, MARK WILLEM; LEDFORD, BRIAN; MALTAIS, FRANCOIS; PENNEY, MARINA; TAKEMOTO, DARIN; WAAL, NATHAN D.; WANG, TIANSHENG AND LI, PAN

FGA Letters patent sealed or granted (standard patent)